Background: Elevated serum levels of Prostate Specific Antigen (PSA) are used as a tumor marker in the detection of prostatic malignancy, in monitoring of wide spectra of prostatic diseases and in formulating various treatment plans of cancer. The use of PSA is a much debated issue in the international literature till date. Keeping the practical difficulties in mind often experienced by our clinicians, further comprehensive clinicopathological and biochemical studies are recommended to explore and utilize the full potential of PSA including its newer parameters especially tailored to suit the Indian population.
INTRODUCTION
Prostate cancer (PCa) is the most common cancer among men in most western populations, and one out of every six men develope PCa during life time 1 . Prostate Cancer (PCa) is a sex hormone dependent cancer in man that varies in its incidence substantially according to geographic region, race and ethinicity. The foremost risk factors that may underlie these regional/ethnic differences are associated endocrine variations and obesity 2, 3 . Widespread testing of serum prostate specific antigen (PSA) has been available for little more than a decade for detection of prostate cancer 4 . In the early years of PSA testing (back in the early 1990s), it was generally believed that a "normal" PSA level was anything between 0 and 4 ng/ml. Majority of PSA is produced in the transitional zone of prostate. The elevated serum levels are used as a tumor marker in the detection of prostatic malignancy, in monitoring of wide spectra of prostatic diseases and in formulating various treatment plans accordingly.
Beside PSA produce by the cancer cells may also vary according to the grade of cancer. High grade cancer cells usually tend to lose their ability to shed tumor markers and a gleason grade 5 prostatic cancer may produce less PSA than a grade 3 cancer. Today we know that PSA levels on their own are simply not good indicators of immediate prostate cancer risk, there is a reason to suspect that PSA levels may be a far more accurate indicator of asymptomatic, low grade prostate infection than of cancer and this approach has led to a new category of asymptomatic prostatitis . On other hand acute prostatitis not only produces large increases in serum PSA but also the return to the baseline depends upon the resolution of infection which may require six to eight weeks or longer. There is a reason to suspect that PSA levels may be a far more accurate indicator of asymptomatic, low grade prostate infection than of cancer and this approach has led to a new category of asymptomatic prostatitis.
Thus, there appears to be a grey zone long the spectrum of prostatic diseases where serum PSA tends to lose their diagnostic potential and call for a proper and comprehensive Clinico-investigative correlation. The use of PSA is a much debated issue in the international literature till this date. Keeping the practical difficulties in mind often experienced by our clinicians, further comprehensive clinicopathological and biochemical studies are recommended to explore and utilize the full potential of PSA including its newer parameters especially tailored to suit the Indian population. Hence this study was planned with the objective to observe the significance of serum PSA for establishing differential diagnosis of prostatic diseases and its impact on the therapeutic plan.
MATERIALS AND METHODS
A total of 232 cases of prostatic diseases recruited from the urology department or referred to Pathology were selected as participants for the study. All the participants signed the informed consent. The protocol of this study was obtained from Ethics committee of C.S.M Medical University. All the participants were subjected to comprehensive Clinicoinvestigative work up including routine hematological and biochemical investigations especially complete haemogram and urine examination, liver and kidney function tests. Ultrasonographic examinations of kidney, ureter and bladder (KUB) were done on all cases and prostate volume was recorded. Transrectal ultrasonography (TRUS) was performed on 172 cases. Uroflowmetry was done after consent in cases, where feasible. The previous clinical, radiological and pathologic findings were recorded in all patients on follow up for different prostatic diseases. Measurement of total as well as free fraction of serum PSA was done by Enzyme immunometric assay on all fresh and follow up patients. Free/Total PSA, Prostate Specific Antigen Density (PSAD) and Prostate Specific Antigen Doubling Time (PSADT) were calculated according to the formulas, PSAD = Total PSA level/Prostate volume on TRUS, PSADT =log 2X time/log (final PSA) -log (initial PSA).An informed consent has been taken at the time of the recruitment of the patients. Patients suffering from diabetes, chronic liver, kidney, heart disease, those taking lipid-lowering drugs or 5-alpha reductase inhibitors were excluded from the study.
Pathological Examination
Prostate biopsies and transurethral resection of prostate (TURP) specimens were procured wherever indicated and processed routinely. Conventional haematoxylin and eosin stained sections were examined for morphologic diagnosis and typing of tissue.
Statistical Analysis
The data was analyzed using statistical software SPSS version 11. Independent Sample t test was performed for quantitative data. Chisquare test of exact probabilities was performed for categorical data. The regression analysis was done by Receiver Operating Curve (ROC) curve. Statistical significance was considered at p values < 0.05.
RESULTS
The study included a total of 232 cases of different prostatic diseases as categorized on the basis of clinical and histopathological diagnosis, including Chronic Prostatitis, Benign prostatic hyperplasia (BPH), Benign hyperplasia of prostate with Prostatitis, High grade Prostatitis Intra Epithelio Neoplasia (PIN) and Prostatic Carcinoma. Histopathology was suspicious for but not diagnostic of malignancy in 5 cases and these cases were classified into a relatively recent group of Atypical Proliferation (ASAP). No definite diagnosis could be recorded in 6 of the patients and these were excluded from the statistical analysis.
Age-wise Distribution
The age of the patients ranged broadly from 40 years to more than 80 years as shown in Table 1 . The maximum number of patients belonged to the age group of 61-65 years (25%) followed by 66-70 years (23.71%). Significant difference was observed amongst the different age groups. BPH was more common in 61-65 years (31.72%) while carcinoma was more commonly seen in 66-70 years (34.48%). Other high-risk categories like PIN and ASAP showed similar pattern with 66-70 year age group (38.46% and 40% respectively) being predominantly affected. Prostatitis showed high prevalence in 56 years of age group onwards. Thus the distribution of patients with various prostatic conditions varied significantly across different age groups (p < 0.05).
Serum PSA levels and PSA parameters
Measurements of Serum PSA, total PSA levels and free PSA levels was done on all the 226 cases at their initial presentation. Subsequent PSA analysis was done on 66 cases at their follow up visits. TRUS was done in 176 cases to calculate PSAD. (Table 2) All cases were assigned to different clinico-pathologic diagnostic categories including prostatitis, BPH with prostatitis, BPH, high grade PIN,ASAP and carcinoma (5.60%, 9.05%, 62.5%, 5.17% & 12.93%) respectively no diagnosis could be recorded in these 6 of the patients ( Table 1 ) and these were excluded from the statistical analysis. The mean total PSA values drastically fell at the subsequent analysis, 2) . The expected cut off value for subsequent total PSA was found to be 9.42 ng/ml at 80% sensitivity in our study postulating that total PSA level at 9.42 ng/ml the probability of detecting true carcinoma cases would be 93% and only 7% cases would be likely to be missed ( Table 3 , ROC Figure 1 ). Receiver Operating Characteristic (ROC) shows the tradeoff between sensitivity and specificity (any increase in sensitivity will be accompanied by a decrease in specificity). The closer the -Unpaired t test, * -Significant P < 0.05, ** -Highly Significant P < 0.001, N -Number of Cases, BPH -Benign Prostatic Hyperplasia, PIN -Prostatic Intra Epithelial Neoplasia, ASAP -Atypical Small Acinar Proliferation, t-PSA -Total Prostate Specific Antigen, f-PSA -Free Prostate Specific Antigen, F/T PSA -Free/Total Prostate Specific Antigen, PSAD -Prostate Specific Antigen Density, DT -Doubling Time.
 Cases of prostatitis, BPH with prostatitis and BPH were included in the benign category while histopathologically confirmed cases of carcinoma constituted the other category.  Statistically significant differences were found for T-PSA, T-PSA (Second analysis), F-PSA, F-PSA (Second analysis) and doubling time.
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Issue 3 curve follows the left-hand border and then the top border of the ROC space, the more accurate the test. ROC curve analysis for the cumulative benign prostatic conditions versus confirmed malignant cases revealed good predictive ability for only PSA doubling time (AUC = 0.898), subsequent total PSA (AUC = 0.898) and subsequent free PSA (AUC = 0.771) in that order (Table 4) , the area under the curve is a measure of text accuracy.
DISCUSSION
The exact statistics regarding incidence of PCa in India is unknown but the rate of incidence is quite low as compared to the western world. The disease usually progresses imperceptibly. Patients generally do not experience symptoms during the early stages and are unlikely to seek medical help until the disease has progressed. Thus, prostate cancer is a major health care problem and research is continued to evaluate the markers for early detection.
The etiology of prostate cancer remains largely unknown, despite of high morbidity. Advancing age, race, and a family history of prostate cancer are the only established risk factors. Many putative risk factors, including androgens, diet, physical activity, sexual factors, inflammation, and obesity, have been implicated, but their roles in prostate cancer etiology remain unclear. The complete Clinicoinvestigative was recorded for each case and their serum total and free PSA levels were measured. Histopathological examination was done biopsy or TURP tissue, wherever feasible and all cases were assigned to different clinicopathologic diagnostic categories including prostatitis, BPH with prostatitis, BPH, high grade PIN, ASAP and carcinoma (5.60%, 9.05%, 62.5%, 5.17%, & 12.93% respectively) no diagnosis could be recorded in these 6 of the patients ( Table 1 ) and these were excluded from the statistical analysis. The age wise distribution of these cases revealed a significant difference (p = 0.031) with majority of the patients belonging to 61-70 years age group. BPH was found to be more prevalent in 61-65 years while carcinoma was more commonly seen in 66-70 year group. These findings may be attributed to the age related volume changes in the prostate that are related to the development of BPH and Carcinoma. Ornstein DK 5 et al presented the concept that age related references range would improve cancer detection rates in younger men and would increases the specificity of PSA testing in older men . 6 For Univariate statistical analysis, the clinically and histopathogically diagnosed cases (n =226) were sub categorized into benign conditions. Carcinoma and an intermediate category of high grade PIN as well as ASAP. The benign category included the heterogeneous group of prostatitis, BPH with prostatitis and BPH.
Prostatitis has now come to known as an important cause of PSA elevation. Acute prostatitis can lead to an increase in PSA, which usually returns to normal levels with appropriate antibiotics within 1-3 months. Patients with chronic prostatitis have a less well defined decrease in PSA after an antibiotic course. Histological prostatitis is a common entity in men without clinical prostatitis. Although it has been reported that acute inflammation is necessary to cause PSA elevation, there is growing evidence that subclinical inflammation may also contribute to rises in PSA levels.
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The relationship of prostatitis and the PSA increase continues to stimulate dispute, and we suggest that the findings mentioned above are not sufficient to explain the reason for the PSA increase.
Yaman O, et al 7 found the aggressiveness grade of the inflammation in subclinical prostatitis to be the most important morphological factor that is responsible for PSA elevation. In our study, the mean total PSA level at initial presentation was found to be quite high in prostatitis patients (86.39 ng / ml + SD 110.13) and showed a striking fall at subsequent intervals after antimicrobial therapy, close to the optimum references range (mean 4.48 ng/ml + SD 3.20). On the other hand, patients with BPH associated with Histologic prostatitis had a mean PSA level (22.69 + SD 18.97), which fell down to (6.92 + SD 7.53). These findings of elevated PSA could be attributed to the large population pool of prostatitis. The characteristics habitat and populations characteristics indicate towards the endemicity of prostatitis in India. Prostatitis is highly prevalent in the form of chronic, smoldering disease and manifests in a spectrum of presentations. The surprisingly elevated PSA range highlights the unexplored biological of prostatitis in India. Secondly, majority of the patients who constituted cases for our study presented to the especially outdoor unit of Urology, with acute exacerbations of LUTS 11 .In these cases, highly elevated PSA levels could be attributed to the renewed inflammatory activity in the prostate and suggests clinically, Acute on chronic prostatitis. The rapid post treatment decline in this particular cohort of cases supports this explanation.
As far as western literature is concerned (Cheol Kwakab etal 2003) 12 reviewed the chronic Prostatitis cohort group under the chronic Prostatitis collaborative research network and found frequent evidence of inflammation in the expressed prostatic secretions (EPSs) or on the prostatic biopsy specimens in asymptomatic men with elevated serum PSA levels. The markedly higher values of serum total PSA in such patients showed a significant statistical difference from the control population but were close to the normal PSA range that most clinicians adhere to. However the mean total PSA values drastically fell at the subsequent analysis, both for the benign as well as malignant categories to 4.82 + 4.37 and 24.76 + 22.96 respectively and could be attributed to the clinical monitoring and management. These findings emphasize the impact of close surveillance as well as prompt management and highlight the importance of frequent serial PSA measurements. ROC curve analysis for the cumulative benign prostatic conditions versus confirmed malignant cases revealed good predictive ability for only PSA doubling time (AUC = 0.898), subsequent total PSA (AUC = 0.898) and subsequent free PSA (AUC = 0.771) in that order ( Table 3) .
CONCLUSION
These findings bear important implications as serial total PSA estimation over frequent intervals of time reflect promising potential in decreasing the need for repeated prostate biopsies in our domestic set up. Our study is a pilot study is an attempt to record the current status of serum PSA in different prostate diseases conditions in the Indian study. Few limitations of the studies are discussed in order to pave the way for future studies in the same direction. Despite the ongoing debate regarding optimal strategy for early detection of prostate cancer with PSA, it is expected to be relevant and critical diagnostic aid in Indian population for a long time to come.
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